Encouragingly, two selective CDK8/19 inhibitors, RVU120 and BCD-115, are undergoing clinical trials for cancer therapy 21, 22, and the adverse effects of some CDK8/19 inhibitors have been revealed to be due to the off-target impacts and improper dose selection 23. This evidence concerns the gene CDK8 and cancer.